Sofosbuvir plus Ribavirin for 12 or 24 Weeks for Patients with HCV Genotype 2 or 3: the VALENCE trial

Zeuzem, S ; Dusheiko, GM ; Salupere, R ; Mangia, A ; Flisiak, R ; Hyland, RH ; Illeperuma, A ; Svarovskaia, ES ; Brainard, DM ; Symonds, WT ; McHutchison, JG ; Weiland, O ; Reesink, HW ; Ferenci, P ; Hezode, C ; Esteban, R

HEPATOLOGY, 2013, Vol.58, p.733A [Periódico revisado por pares]

Texto completo disponível